非康复期血清中缺乏中和活性，无论ABO血型和抗A同种凝集素效价如何。
Lack of neutralizing activity in nonconvalescent sera, regardless of ABO blood group and anti-A isoagglutinin titer.
作者信息
Focosi Daniele, Rosellini Alfredo, Spezia Pietro Giorgio, Macera Lisa, Lanza Maria, Paolicchi Aldo, Biagini Denise, Baj Andreina, Pistello Mauro, Maggi Fabrizio
机构信息
North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
Division of Virology, Pisa University Hospital, Italy.
出版信息
J Clin Virol Plus. 2021 Sep;1(3):100035. doi: 10.1016/j.jcvp.2021.100035. Epub 2021 Aug 8.
BACKGROUND
Several ABO blood groups have been associated with the likelihood of infection, severity, and/or outcome of COVID-19 in hospitalized cohorts, raising the hypothesis that anti-A isoagglutinins in non-A-group recipients could act as neutralizing antibodies against SARS-CoV-2.
MATERIALS AND METHODS
We run live virus neutralization tests using sera from 58 SARS-CoV-2 seronegative blood donors (27 O-group and 31 A-group) negatives for SARS-CoV-2 IgG to investigate what degree of neutralizing activity could be detected in their sera and eventual correlation with anti-A isoagglutinin titers.
RESULTS
We could not find clinically relevant neutralizing activity in any blood group, regardless of anti-isoagglutinin titer.
DISCUSSION
Our findings suggest that mechanisms other than neutralization explain the differences in outcomes from COVID19 seen in different ABO blood groups.
背景
在住院患者队列中，几种ABO血型与感染新型冠状病毒肺炎（COVID-19）的可能性、严重程度和/或预后相关，这引发了一种假设，即非A血型受者体内的抗A同种凝集素可能作为针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的中和抗体。
材料与方法
我们使用58名新型冠状病毒2血清阴性献血者（27名O型血和31名A型血）的血清进行活病毒中和试验，这些献血者的新型冠状病毒2免疫球蛋白G（SARS-CoV-2 IgG）呈阴性，以研究在他们的血清中能检测到何种程度的中和活性，以及与抗A同种凝集素滴度的最终相关性。
结果
无论抗同种凝集素滴度如何，我们在任何血型中均未发现具有临床意义的中和活性。
讨论
我们的研究结果表明，除中和作用外的其他机制可解释不同ABO血型中COVID-19的预后差异。
Zotero 插件